- Home
- TARS vs SOC Comparison
TARS vs SOC Comparison
Compare TARS & SOC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TARS | SOC |
|---|---|---|
| Founded | 2016 | 2020 |
| Country | United States | United States |
| Employees | N/A | 200 |
| Industry | Medicinal Chemicals and Botanical Products | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.2B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | TARS | SOC |
|---|---|---|
| Price | $62.93 | $14.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $89.00 | $17.33 |
| AVG Volume (30 Days) | 628.4K | ★ 2.5M |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.21 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $451,360,000.00 | N/A |
| Revenue This Year | $56.43 | N/A |
| Revenue Next Year | $30.19 | $73.55 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 146.71 | N/A |
| 52 Week Low | $38.51 | $3.72 |
| 52 Week High | $85.25 | $32.18 |
Technical Indicators
Market Signals| Indicator | TARS | SOC |
|---|---|---|
| Relative Strength Index (RSI) | 46.29 | 53.88 |
| Support Level | $60.38 | $11.79 |
| Resistance Level | $67.24 | $14.82 |
| Average True Range (ATR) | 3.60 | 0.96 |
| MACD | 0.28 | 0.14 |
| Stochastic Oscillator | 53.36 | 70.17 |
Price Performance
Historical ComparisonAbout TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
About SOC Sable Offshore Corp.
Sable Offshore Corp is a Houston-based independent upstream company focused on developing the Santa Ynez Unit in federal waters offshore California. The company operates as one reportable oil and gas segment and is engaged in the acquisition, development, exploration, and production of oil and natural gas.